Equities

Bausch Health Companies Inc

Bausch Health Companies Inc

Actions
  • Price (EUR)9.60
  • Today's Change0.559 / 6.18%
  • Shares traded0.00
  • 1 Year change+38.19%
  • Beta--
Data delayed at least 15 minutes, as of Mar 28 2024 07:05 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

  • Revenue in CAD (TTM)11.88bn
  • Net income in CAD-803.17m
  • Incorporated2013
  • Employees20.27k
  • Location
    Bausch Health Companies Inc2150 Saint-Elzear Blvd WLAVAL H7L 4A8CanadaCAN
  • Phone+1 (514) 744-6792
  • Fax+1 (514) 744-6792
  • Websitehttps://www.bauschhealth.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.